SBIR/STTR Research Award

Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

Award identifier 952785554d94be4e335a9411229a4a8d062334fc4d559e3a1f7c9851045ec542Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,949,208

Program and phase

STTR · Phase II

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NeuroSigma, Inc.
Proposal award date
2016-02-15
Contract end date
2020-01-31
UEI
Not reported
Solicitation number
PA14-072
Topic code
101

Research abstract

DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortalityIn recent years a new type of minimallyinvasive endovascular device to treat aneurysms has been introduced to the marketThese devicesknown as flow diverting stentsare composed of a tubular metal mesh and are placed in the parent artery to cover the neck of the aneurysm being treatedThe small pores in the mesh prevent blood from entering the aneurysmwhich causes blood trapped inside the aneurysm to become stagnant and clotThe aneurysm then undergoes a process of healing with the stent acting as a scaffold for reconstruction of the parent arteryDespite their successfirst generation flow diverters suffer from a number of limitations such as delayed aneurysm occlusionoften on the order of monthsand the need for multiple devices per patient to achieve complete occlusionIn as many asof patients complete occlusion is never achievedNeuroSigma s next generation flow diverter is based on Thin Film NitinolTFNtechnologyTFN is an advanced biomaterial fabricated on silicon wafers that overcomes many of the limitations associated with first generation flow divertersResults from animal studies suggest that the TFN flow diverter gives superior rates of aneurysm occlusion and faster parent artery repair than first generation devicesThe purpose of this project is to build upon these intriguing findings an develop a "rapid occlusion" flow diverterwhere placement of a single device results in speedydefinitive aneurysm repairAt the completion of this project the TFN flow diverter will be ready t begin firstin human studies as an improved treatment for the millions who suffer from intracranial aneurysms worldwide

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.